Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma
2020 · New England Journal of Medicine · 1,443 citations
https://doi.org/10.1056/nejmoa2002788
T
Thomas Powles
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
682
Papers
36.5K
Citations
77
h-index
247
i10-index
Thomas Powles is an academic researcher from St Bartholomew's Hospital. The author has contributed to research in topics: Bladder and Urothelial Cancer Treatments & Cancer Immunotherapy and Biomarkers & Urinary and Genital Oncology Studies. The author has an h-index of 77, co-authored 580 publications.
ORCID: 0000-0001-7760-4724Papers by this author
worksAtezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial
2017 · The Lancet · 1,400 citations
https://doi.org/10.1016/s0140-6736(17)33297-x
Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer
2024 · New England Journal of Medicine · 810 citations
https://doi.org/10.1056/nejmoa2312117
The cancer-immunity cycle: Indication, genotype, and immunotype
2023 · Immunity · 736 citations
https://doi.org/10.1016/j.immuni.2023.09.011
COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study
2020 · The Lancet Oncology · 599 citations
https://doi.org/10.1016/s1470-2045(20)30442-3
A review on the evolution of PD-1/PD-L1 immunotherapy for bladder cancer: The future is now
2017 · Cancer Treatment Reviews · 393 citations
https://doi.org/10.1016/j.ctrv.2017.01.007
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat